0001387131-13-000206.txt : 20130130 0001387131-13-000206.hdr.sgml : 20130130 20130130104814 ACCESSION NUMBER: 0001387131-13-000206 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130125 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130130 DATE AS OF CHANGE: 20130130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26372 FILM NUMBER: 13557527 BUSINESS ADDRESS: STREET 1: 11455 EL CAMINO REAL STREET 2: SUITE 310 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11455 EL CAMINO REAL STREET 2: SUITE 310 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 8-K 1 admp-8k_012513.htm CURRENT REPORT admp-8k_012513.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported):  January 25, 2013
 
 
ADAMIS PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
 
Delaware
  
0-26372
  
82-0429727
(State or other jurisdiction
of incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)
         
         
 11455 El Camino Real, Suite 310
Del Mar, CA
        
92130
(Address of Principal Executive Offices)
        (Zip Code)
         
 
Registrant’s telephone number, including area code: (858) 997-2400

(Former name or Former Address, if Changed Since Last Report.)
 
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 
 
Item 8.01                      Other Events
 
As the Company has previously reported in reports on Form 8-K and other periodic reports that we have filed with the Securities and Exchange Commission, on June 11, 2012, we completed the closing of a private placement financing transaction with The G-Max Trust (“G-Max”) pursuant to which we issued a Convertible Promissory Note (the “Note”) to G-Max and 500,000 shares of common stock for aggregate gross proceeds of approximately $500,000.  Principal and accrued and unpaid interest under the Note was due and payable on April 1, 2013.  The Note was convertible into shares of the Company’s common stock at any time at the discretion of G-Max at a conversion price per share of $0.55.
 
During January 2013, G-Max elected to convert all of the remaining unconverted principal of the Note and related interest into shares of common stock, and the Note is no longer outstanding.  This conversion is in addition to the previously reported conversion by Gemini Master Fund, Ltd. of all of the remaining portion of its $1.0 million senior convertible note, originally issued on April 2, 2012, into shares of common stock before the January 2, 2013 maturity date of that note.
 

Item 9.01. 
Financial Statements and Exhibits.
 
 
(d) 
Exhibits
                                           
                                         None.
 
 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
       
ADAMIS PHARMACEUTICALS CORPORATION
         
         
Dated:
  
 January 30, 2013.
      
By:
  
/s/ Robert O. Hopkins
           
Name:
  
Robert O. Hopkins
           
Title:
  
Chief Financial Officer